There isn't a standard Semax dosage established by Western clinical trials. The amounts on record come from Russian prescribing information and small Russian studies. A prescriber sets any actual dose, timing, and follow-up.
A dose-finding study compares several amounts to see how results and unwanted effects change. No Western study has established that balance for Semax. A number used during stroke recovery doesn't become an everyday focus dose.
The same distinction runs through the Selank dosage evidence: a study amount describes what researchers tested, while an individual prescription needs its own decision.
What Semax dosage do the Russian labels describe?
Semax is a peptide, a short chain of protein building blocks. Russia's registered products contain Semax alone and have different strengths and uses.
As of October 1, 2026, the day this article was written, the manufacturer's published 0.1% prescribing information and 1% prescribing information describe, among other uses, the amounts below. These are Russian label facts, with the units translated into English.
One milligram (mg) equals 1,000 micrograms (mcg). Ischemic stroke means a blocked vessel cuts blood flow to part of the brain. Optic-nerve disease affects the nerve carrying visual signals from the eye to the brain.
| Russian nasal-drop product | Registered use | Daily amount stated on the label | Course stated on the label |
|---|---|---|---|
| 0.1% | Prevention of mental fatigue during demanding work | “400–900 mcg/day” | 3–5 days |
| 0.1% | Optic-nerve disease, using nasal drops | “600–900 mcg/day” | 7–10 days |
| 1% | Moderate acute ischemic stroke, alongside other treatment | “6,000–12,000 mcg/day” | 10 days |
| 1% | Severe acute ischemic stroke, alongside other treatment | “12,000–20,000 mcg/day” | 10 days |
The 0.1% label also lists other uses not shown here, including memory and thinking problems linked to blood-vessel disease of the brain, each with its own amounts and course. The percentages describe concentration, the amount of Semax in a set volume of liquid. The 1% product contains ten times as much per equal volume as the 0.1% product.
Those differences explain why an online chart can look precise while leaving out the most important detail: which medicine, for which condition?
What Semax dose did the studies use?
A 2018 study by Gusev and colleagues in Zhurnal Nevrologii i Psikhiatrii followed 110 people after ischemic stroke. The Russian full text describes random assignment to Semax or no Semax within groups starting rehabilitation earlier or later. Rehabilitation is care aimed at recovering everyday abilities.
The Semax groups received 6 mg daily through the nose, in two 10-day courses with a 20-day break between them. Other rehabilitation care continued in both groups. Researchers used one Semax amount; they didn't compare several doses to find a starting point or an upper limit.
Polunin and colleagues' 2000 abstract in Vestnik Oftalmologii describes three groups with optic-nerve disease. One received nasal drops, another received medicine through nasal tissue using a small electrical current, and the third was a comparison group. Semax was added to other treatment.
That paper's available abstract reports no amount or course length. A dose from the Russian label cannot fill that blank and then be presented as the study's dose.
Why a Russian label dose doesn't transfer
The condition comes first. A stroke-care amount answers a different question from an amount studied for mental fatigue. The larger number doesn't establish a stronger focus effect.
The route, meaning how a medicine enters the body, matters too. A nasal amount cannot be converted into an amount for another route without evidence about absorption, how much enters the body. Even two nasal preparations can differ in strength and delivery device.
The Semax/Selank nasal-spray guide explains those device questions; the research used nasal drops and sprays, while the blend Promise offers is an injectable vial. A drop in a Russian bottle and an application from another device don't necessarily deliver the same amount.
Adding Selank changes the preparation again. A Semax-only label or study doesn't establish dosing for the pair. The Semax/Selank product card connects to the current product page and visit information.
N-acetyl Semax amidate is another separate question: it changes both ends of the Semax molecule. An online amount for that modified molecule doesn't establish an equivalent amount of ordinary Semax. A smaller suggested number is not evidence that the modified peptide has a stronger effect.
Semax dosing frequency and cycle length
There isn't one established Semax cycle length. The short courses in the table belong to particular Russian indications, meaning reasons for treatment. The 2018 study's break was part of its study plan. Neither establishes a repeating schedule for ongoing focus use.
As of October 1, 2026, the day this article was written, PubMed and ClinicalTrials.gov searches identified no Western dose-finding study. The ClinicalTrials.gov public search returned zero Semax records; that describes this registry, rather than every study worldwide.
FDA's review dated May 11, 2026 also found no human pharmacokinetic study, a measurement of how a drug enters, moves through, and leaves the body. The guide to Semax's unknown timing explains why that gap cannot supply a dosing clock.
What the July FDA recommendation means for dosing
As of October 1, 2026, the day this article was written, the July 24 FDA advisory votes remain relevant to this discussion. The official recording shows eight votes in favor, five against, and one abstention for each Semax ingredient considered. The recommendation concerned a compounding ingredient list. It supplied no dose for focus and did not approve a finished medicine.
Semax is not FDA-approved in the United States. A compounded medication is prepared by a pharmacy for an individual prescription. A compounded Semax/Selank preparation is different from an FDA-approved product and is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.
Semax's FDA history follows the separate regulatory record. An ingredient-list recommendation cannot fill the missing dose-comparison studies.
What a provider considers before setting a dose
The review begins with the goal and whether the evidence fits it. It includes other medicines, blood pressure history, previous seizures, mental-health conditions, allergies, pregnancy, and breastfeeding.
Both Russian labels list seizure history, acute mental-health conditions, anxiety-related disorders, pregnancy, and breastfeeding among reasons those products aren't used. These are label restrictions, rather than measured rates of reactions. The labels also flag nasal medicines that narrow blood vessels in the nose.
The Semax side-effects guide covers the safety evidence. The separate explanation of how Semax works describes the biological research; a proposed mechanism doesn't choose a person's dose.
What the prescription needs to settle
An individual plan identifies the exact preparation, strength, route, amount, timing, and point for reassessment. It also identifies who handles questions and possible reactions. More decimal places in an online chart cannot replace those decisions.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If a prescription is written, the prescriber sets the actual dose and follow-up plan. The Russian label and study numbers provide background for that conversation, not an amount to copy.
